Neurotoxin 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-Induced Animal Models for Parkinson's Disease

Animal Models for the Study of Human Disease

Volumn , Issue , 2013, Pages 633-650

  Kasahara, Jiro ^a   Choudhury, Mohammed Emamussalehin ^b,c   Yokoyama, Hironori ^a   Kadoguchi, Naoto ^a   Nomoto, Masahiro ^b  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

^b EHIME UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c LAVAL UNIVERSITY   (Canada)

Author keywords

Common marmoset; Dopamine; Mouse; MPTP; Parkinson's disease; Striatum; Substantia nigra pars compacta

Indexed keywords

EID: 84902032640     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-415894-8.00026-9     Document Type: Chapter

References (114)

1. J. Parkinson (1817) An Essay on the Shaking Palsy. London: Sherwood, Neely and Jones
2. J.M. Chacot (1880) Lecon sur les Maladies du Systeme Nerveux. 4th ed. Paris: Tome Premier
3. Tretiakoff C. Contribution of a I’Etude de I’Anatomie Pathologique du Locus Niger. These de Paris; 1919.
4. A. Carlsson (1959) The occurrence, distribution and physiological role of catecholamines in the nervous system. Pharmacol Rev 11 490-493.
5. H. Ehringer and O. Hornykiewicz (1960) Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system. Klin Wochenshr 38 1236-1239.
6. D.C. German, K. Manaye, W.K. Smith, et al. (1989) Ann Neurol 26 507-514.
7. Y. Ma, V. Dhawan, M. Mentis, et al. (2002) Parametric mapping of [18F]FPCT binding in early stage Parkinson's disease: a PET study. Synapse 45 125-133.
8. J. Jankovic and C.D. Marsden (1988) Parkinson's Disease and Movement Disorders. Baltimore: Urban/Schwarzenberg
9. P. Krack, M.I. Hariz, C. Baunez, et al. (2010) Deep brain stimulation: from neurology to psychiatry? Trends Neurosci 33 474-484.
10. O. Rascol, A. Lozano, M. Stern, et al. (2011) Milestones in Parkinson's disease therapeutics. Mov Disord 26 1072-1082.
11. E.V. Encarnacion and R.A. Hauser (2008) Levodopa-induced dyskinesias in Parkinson's disease: etiology, impact on quality of life, and treatments. Eur Neurol 60 57-66.
12. M.S. Trivedi and T. Jarbe (2011) A brief review on recent developments in animal models of schizophrenia. Indian J Pharmacol 43 375-380.
13. H. Kishima, T. Poyot, J. Bloch, et al. (2004) Encapsulated GDNF-producing C2C12 cells for Parkinson's disease: a pre-clinical study in chronic MPTP-treated baboons. Neurobiol Dis 16 428-439.
14. H. Saiki, T. Hayashi, R. Takahashi, et al. (2010) Objective and quantitative evaluation of motor function in a monkey model of Parkinson's disease. J Neurosci Methods 190 198-204.
15. M.E. Choudhury, T. Moritoyo, H. Yabe, et al. (2010) Zonisamide attenuates MPTP neurotoxicity in marmosets. J Pharmacol Sci 114 298-303.
16. O. Ghiribi, M.M. Herman, P. Pramoonjago, et al. (2003) MPP+ induces the endoplasmic reticulum stress response in rabbit brain involving activation of the ATF-6 and NF-kappaB signaling pathways. J Neuropathol Exp Neurol 62 1144-1153.
17. C.B. Choi, S.Y. Kim, S.H. Lee, et al. (2011) Assessment of metabolic changes in the striatum of a MPTP-intoxicated canine model: in vivo 1H-MRS study of an animal model for Parkinson's disease. Magn Reson Imaging 29 32-39.
18. J.S. Schneider and D.S. Rothblat (1991) Neurochemical evaluation of the striatum in symptomatic and recovered MPTP-treated cats. Neuroscience 44 421-429.
19. A. Barbeau, L. Dallaire, N.T. Buu, et al. (1985) New amphibian models for the study of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Life Sci 36 1125-1134.
20. J. Park, S.Y. Kim, G.H. Cha, et al. (2005) Drosophila DJ-1 mutants show oxidative stress-sensitive locomotive dysfunction. Gene 361 133-139.
21. E. Braungert, M. Gerlach, P. Riederer, et al. (2004) Caenorhabditis elegans MPP+ model of Parkinson's disease for high-throughput drug screenings. Neurodegener Dis 1 175-183.
22. D.M. Crabtree and J. Zhang (2012) Genetically engineered mouse models of Parkinson's disease. Brain Res Bull 88 13-32.
23. F. Blandini and M.T. Armentero (2012) Animal models of Parkinson's disease. FEBS J 279 1156-1166.
24. J.W. Langston, P. Ballard, J.W. Terud, et al. (1983) Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219 979-980.
25. M. Nomoto, S. Kita, S.I. Iwata, et al. (1998) Effects of acute or prolonged administration of cabergoline on parkinsonism induced by MPTP in common marmosets. Pharmacol Biochem Behav 59 717-721.
26. T. Araki, T. Kumagai, K. Tanaka, et al. (2001) Neuroprotective effect of riluzole in MPTP-treated mice. Brain Res 918 176-181.
27. Y. Muramatsu, R. Kurosaki, T. Mikami, et al. (2002) Therapeutic effect of neuronal nitric oxide synthase inhibitor (7-nitroindazole) against MPTP neurotoxicity in mice. Metab Brain Dis 17 169-182.
28. H. Yokoyama, H. Kuroiwa, T. Tsukada, et al. (2010) Poly(ADP-ribose)polymerase inhibitor can attenuate the neuronal death after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in mice. J Neurosci Res 88 1522-1536.
29. H. Yokoyama, H. Kuroiwa, R. Yano, et al. (2010) Therapeutic effect of a novel anti-Parkinsonian agent zonisamide against MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) neurotoxicity in mice. Metab Brain Dis 25 135-143.
30. L.M. de Lau and M.M. Breteler (2006) Epidemiology of Parkinson's disease. Lancet Neurol 5 525-535.
31. A. Samii, J.G. Nutt and B.R. Ransom (2004) Parkinson's disease. Lancet 363 1783-1793.
32. M. Quik, L.Z. Huang, N. Parameswaran, T. Bordia, C. Campos and X.A. Perez (2009) Multiple roles for nicotine in Parkinson's disease. Biochem Pharmacol 78 677-685.
33. K. Castagnoli and T. Murugesan (2004) Tobacco leaf, smoke and smoking, MAO inhibitors, Parkinson's disease and neuroprotection: are there links? Neurotoxicology 25 279-291.
34. K.S. Bankiewicz, R. Sanchez-Pernaute, Y. Oiwa, et al. (1999) Preclinical models of Parkinson's disease. Curr Protocol Neurosci 9.4.1–9.4.32
35. C.R. Swanson, V. Joers, V. Bondarenko, et al. (2011) The PPAR-γ agonist pioglitazone modulates inflammation and induces neuroprotection in parkinsonian monkeys. J Neuroinflammation 8 91-104.
36. T. Nagatsu and M. Sawada (2007) Biochemistry of postmortem brains in Parkinson's disease: historical overview and future prospects. J Neural Transm Suppl (72), 113-120.
37. L.S. Forno (1996) Neuropathology of Parkinson's disease. J Neuropathol Exp Neurol 55 259-272.
38. H.Q. Wang and R. Takahashi (2007) Expanding insights on the involvement of endoplasmic reticulum stress in Parkinson's disease. Antioxid Redox Signal 9 553-561.
39. C.T. Cachón-González Cox T. (2012) The cellular pathology of lysosomal disease. J Pathol 226 241-254.
40. T. Calí, D. Ottolini and M. Brini (2011) Mitochondria, calcium, and endoplasmic reticulum stress in Parkinson's disease. Biofactors 37 228-240.
41. L.M. Collins, A. Toulouse, T.J. Connor, et al. (2012) Contributions of central and systemic inflammation to the pathophysiology of Parkinson's disease. Neuropharmacology 62 2154-2168.
42. K. Tieu, H. Ischiropoulos and S. Pzedborski (2003) Nitric oxide and reactive oxygen species in Parkinson's disease. IUBMB Life 55 329-335.
43. L. Minghetti (2004) Cyclooxygenase-2 (COX-2) in inflammatory and degenerative brain diseases. J Neuropathol Exp Neurol 63 901-910.
44. U. Ungerstedt (1968) 6-hydroxy-dopamine induced degeneration of central monoamine neurons. Eur J Pharmacol 5 107-110.
45. U. Ungerstedt and G.W. Arbuthnott (1970) Quantitative recording of rotational behavior in rats after 6-hydroxy-dopamine lesions of the nigrostriatal dopamine system. Brain Res 24 485-493.
46. R. Betarbet, T.B. Sherer and J.T. Greenamyre (2002) Animal models of Parkinson's disease. Bioessays 24 308-318.
47. S. Duty and P. Jenner (2011) Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease. Br J Pharmacol 164 1357-1391.
48. J.W. Langston, L.S. Forno, C.S. Rebert, et al. (1984) Selective nigral toxicity after systemic administration of 1-methyl-4-phenyl-1,2,3,6- tetrahydropyrine (MPTP) in the squirrel monkey. Brain Res 292 390-394.
49. G.A. Ricaurte, I. Irwin, L.S. Forno, et al. (1987) Aging and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrine-induced degeneration of dopaminergic neurons in the substantia nigra. Brain Res 403 43-51.
50. H. Yokoyama, H. Kuroiwa, J. Kasahara, et al. (2011) Neuropharmacological approach against MPTP (1-methyl-4-phenyl-1,2,3,6- tetrahydropyrine)-induced mouse model of Parkinson's disease. Acta Neurobiol Exp 71 1-13.
51. H. Yokoyama, H. Uchida, H. Kuroiwa, et al. (2011) Role of glial cells in neurotoxin-induced animal models of Parkinson's disease. Neurol Sci 32 1-7.
52. Y.M. Wang, P. Pu and W.D. Le (2007) ATP depletion is the major cause of MPP+ induced dopamine neuronal death and worm lethality in alpha-synuclein transgenic C. elegans. Neurosci Bull 2007(23), 329-335.
53. E. Sunderström, A. Fredriksson and T. Archer (1990) Chronic neurochemical and behavioral changes in MPTP-lesioned C57BL/6 mice: a model for Parkinson's disease. Brain Res 528 181-188.
54. M.L. Laret, J.A. San Millián, E. Fabre, et al. (2002) Deprenyl protects from MPTP-induced Parkinson-like syndrome and glutathione oxidation in rat striatum. Toxicology 170 165-171.
55. R.N. Kakaria, M.H. Mitchell and S.I. Harik (1987) Correlation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity with blood–brain barrier monoamine oxidase activity. Proc Natl Acad Sci USA 84 3521-3525.
56. R.E. Heikkila, W.J. Niclas and R.C. Duvoisin (1985) Dopaminergic toxicity after the stereotaxic administration of the 1-methyl-4-phenylpyridinium ion (MPP+) to rats. Neurosci Lett 59 135-140.
57. R.D. Predinger, A.S. Nguiar Jr., F.C. Matheus, et al. (2012) Intranasal administration of neurotoxicants in animals: support for the olfactory vector hypothesis of Parkinson's disease. Neurotox Res 21 90-116.
58. M. Shimoji, L. Zhang, A.S. Mandir, et al. (2005) Absence of inclusion body formation in the MPTP mouse model of Parkinson's disease. Brain Res Mol Brain Res 134 103-108.
59. G. Halliday, M.T. Herrero, K. Murphy, et al. (2009) No Lewy pathology in monkeys with over 10 years of severe MPTP parkinsonism. Mov Disord 24 1519-1523.
60. R. Betarbet, T.B. Sherer, G. MacKenzie, et al. (2000) Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat Neurosci 3 1301-1306.
61. K. Shimizu, K. Ohtaki, K. Matsubara, et al. (2001) Carrier-mediated processes in blood–brain barrier penetration and neural uptake of paraquat. Brain Res 906 135-142.
62. J.R. Richardson, Y. Quan, T.B. Sherer, et al. (2005) Paraquat neurotoxicity is distinct from that of MPTP and rotenone. Toxicol Sci 88 193-201.
63. P.M. Rappold, M. Cui, A.S. Chesser, et al. (2011) Paraquat neurotoxicity is mediated by the dopamine transporter and organic cation transporter-3. Proc Natl Acad Sci USA 108 20766-20771.
64. J. Zhang, V.A. Fitsanakis, G. Gu, et al. (2003) Manganese ethylene-bis dithiocarbamate and selective dopaminergic neurodegeneration in rat: a link through mitochondrial dysfunction. J Neurochem 84 336-346.
65. M. Thiruchelvam, B.J. Brockel, E.K. Richfield, et al. (2000) Potentiated and preferential effects of combined paraquat and maneb on nigrostriatal dopamine systems: environmental risk factors for Parkinson’s disease? Brain Res 873 225-234.
66. R.N. Takahashi, R. Rogerio and M. Zanin (1989) Maneb enhances MPTP neurotoxicity in mice. Res Commun Chem Pathol Pharmacol 66 167-170.
67. E. Aoki, H. Yokoyama, H. Kimoto, et al. (2010) Chronic administration with rotenone does not enhance MPTP neurotoxicity in C57BL/6 mice. J Mol Neurosci 41 17-24.
68. U. Muthane, K.A. Ramsay, H. Jiang, et al. (1994) Differences in nigral neuron number and sensitivity to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in C57/bl and CD-1 mice. Exp Neurol 126 195-204.
69. M. Sedelis, K. Hofele, G.W. Auburger, et al. (2000) MPTP susceptibility in the mouse: behavioral, neurochemical, and histological analysis of gender and strain differences. Behav Genet 30 171-182.
70. N.M. Filipov, A.B. Norwood and S.C. Sistrunk (2009) Strain-specific sensitivity to MPTP of C57BL/6 and BALB/c mice is age dependent. Neuroreport 20 713-717.
71. E. Sunderström, I. Strömberg, T. Tsushumi, et al. (1987) Studies on the effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on central catecholamine neurons in C57BL/6 mice. Comparison with three other strains of mice. Brain Res 405 26-38.
72. L.S. Walsh and G.C. Wanger (1989) Age-dependent effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): correlation with monoamine oxidase-B. Synapse 3 308-314.
73. J.D. Boyd, H. Jang, K.R. Shepherd, et al. (2007) Response to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) differs in mouse strains and reveals a divergence in JNK signaling and COX-2 induction prior to loss of neurons in the substantia nigra pars compacta. Brain Res 1175 107-116.
74. M. Smeyne, O. Goloubeva and R.J. Smeyne (2001) Strain-dependent susceptibility to MPTP and MPP(+)-induced parkinsonism is determined by glia. Glia 34 73-80.
75. R. Kurosaki, Y. Muramatsu, Y. Imai, et al. (2004) Neuroprotective effect of the angiotensin-converting enzyme inhibitor perindopril in MPTP-treated mice. Neurol Res 26 644-657.
76. H. Kuroiwa, H. Yokoyama, H. Kimoto, et al. (2010) Biochemical alterations of the striatum in an MPTP-treated mouse model of Parkinson's disease. Metab Brain Dis 25 177-183.
77. K.S. Hsu, W.M. Fu and S.Y. Lin-Shiau (1994) Blockade by MPTP of the nicotinic acetylcholine receptor channels in embryonic xenopus muscle cells. Neuropharmacology 33 35-41.
78. E. Aoki, R. Yano, H. Yokoyama, et al. (2009) Role of nuclear transcription factor kappa B (NF-kappaB) for MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahyropyridine)-induced apoptosis in nigral neurons of mice. Exp Mol Pathol 86 57-64.
79. R. Yano, H. Yokoyama, H. Kuroiwa, et al. (2009) A novel anti-Parkinsonian agent, zonisamide, attenuates MPTP-induced neurotoxicity in mice. J Mol Neurosci 39 211-219.
80. Y. Watanabe, H. Kato and T. Araki (2008) Protective action of neuronal nitric oxide synthase inhibitor in the MPTP mouse model of Parkinson's disease. Metab Brain Dis 23 51-69.
81. N. Ogawa, K. Mizukawa, Y. Hirose, et al. (1987) MPTP-induced Parkinsonian model in mice: biochemistry, pharmacology and behavior. Eur Neurol 26 16-23.
82. Y. Ohno, K. Ishida, K. Ikeda, et al. (1994) Evaluation of bradykinesia induction by SM-9018, a novel 5-HT2 and D2 receptor antagonist, using the mouse pole test. Pharmacol Biochem Behav 49 19-23.
83. C. Belzung and G. Griebel (2001) Measuring normal and pathological anxiety-like behaviour in mice: a review. Behav Brain Res 125 141-149.
84. R.L. Dean, J. Scozzafava, J.A. Goas, et al. (1981) Age-related differences in behavior across the life span of the C57BL/6J mouse. Exp Aging Res 7 427-451.
85. K. Sato, C. Sumi-Ichinose, R. Kaji, et al. (2008) Differential involvement of striosome and matrix dopamine systems in a transgenic model of dopa-responsive dystonia. Proc Natl Acad Sci USA 105 12551-12556.
86. M. Mohanasundari, M.S. Srinivasan, S. Sethupathy, et al. (2006) Enhanced neuroprotective effect by combination of bromocriptine and Hypericum perforatum extract against MPTP-induced neurotoxicity in mice. J Neurol Sci 249 140-144.
87. S.R. Blume, D.K. Cass and K.Y. Tsueng (2009) Stepping test in mice: a reliable approach in determining forelimb akinesia in MPTP-induced parkinsonism. Exp Neurol 219 208-211.
88. M. Yamada, K. Kida, W. Amutuhaire, et al. (2010) Gene disruption of caspase-3 prevents MPTP-induced Parkinson's disease in mice. Biochem Biophys Res Commun 402 312-318.
89. H. Mochizuki, K. Goto, H. Mori, et al. (1996) Histochemical detection of apoptosis in Parkinson's disease. J Neurol Sci 137 120-123.
90. T. Himeda, Y. Watanabe, H. Tounai, et al. (2006) Time dependent alterations of co-localization of S100beta and GFAP in the MPTP-treated mice. J Neural Transm 113 1887-1894.
91. J.W. Langston (2002) Parkinson's disease: current and future challenger. Neurotoxicol 23 443-450.
92. A. Ghosh, A. Roy, X. Liu, J.H. Kordower, et al. (2007) Selective inhibition of NF-kappaB activation prevents dopaminergic neuronal loss in a mouse model of Parkinson's disease. Proc Natl Acad Sci USA 104 18754-18759.
93. S. Li and X.P. Pu (2011) Neuroprotective effect of kaempferol against a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced mouse model of Parkinson's disease. Biol Pharm Bull 34 1291-1296.
94. N. Kadoguchi, M. Umeda, H. Kato, et al. (2008) Proteasome inhibitor does not enhance MPTP neurotoxicity in mice. Cell Mol Neurobiol 28 971-979.
95. N. Kadoguchi, H. Kimoto, R. Yano, et al. (2008) Failure of acute administration with proteasome inhibitor to provide a model of Parkinson's disease in mice. Metab Brain Dis 23 147-154.
96. F. Fornai, O.M. Schlüter, P. Lenzi, et al. (2005) Parkinson-like syndrome induced by continuous MPTP infusion: convergent roles of the ubiquitin-proteasome system and alpha-synuclein. Proc Natl Acad Sci USA 102 3413-3418.
97. A.H. Nagahara and M.H. Tuszynski (2011) Potential therapeutic uses of BDNF in neurological and psychiatric disorders. Nat Rev Drug Discov 10 209-219.
98. H.C. Hung and E.H. Lee (1996) The mesolimbic dopaminergic pathway is more resistant than the nigrostriatal dopaminergic pathway to MPTP and MPP+ toxicity: role of BDNF gene expression. Brain Res Mol Brain Res 41 14-26.
99. Y.X. Ding, Y. Xia, X.Y. Jiao, et al. (2011) The TrkB-positive dopaminergic neurons are less sensitive to MPTP insult in the substantia nigra of adult C57/BL mice. Neurochem Res 36 1759-1766.
100. S.B. Rangasamy, K. Soderstrom, R.A. Bakay, et al. (2010) Neurotrophic factor therapy for Parkinson's disease. Prog Brain Res 184 237-264.
101. K. Biju, Q. Zhou, G. Li, et al. (2010) Macrophage-mediated GDNF delivery protects against dopaminergic neurodegeneration: a therapeutic strategy for Parkinson's disease. Mol Ther 18 1536-1544.
102. R. Maggio, M. Riva, F. Vaglini, et al. (1998) Nicotine prevents experimental parkinsonism in rodents and induces striatal increase of neurotrophic factors. J Neurochem 71 2439-2446.
103. J.R. Hollerman and A.A. Grace (1990) The effects of dopamine-depleting brain lesions on the electrophysiological activity of rat substantia nigra dopamine neurons. Brain Res 533 203-212.
104. D. Perrin, J. Mamet, H. Scarna, et al. (2004) Long-term prenatal hypoxia alters maturation of brain catecholaminergic systems and motor behavior in rats. Synapse 54 92-101.
105. M.F. Olive, K.K. Mehmert and C.W. Hodge (2000) Microdialysis in the mouse nucleus accumbens: a method for detection of monoamine and amino acid neurotransmitters with simultaneous assessment of locomotor activity. Brain Res Brain Res Protoc 5 16-24.
106. J.Y. Chen, P.C. Hsu, I.L. Hsu, et al. (2001) Sequential up-regulation of the c-fos, c-jun and bax genes in the cortex, striatum and cerebellum induced by a single injection of a low dose of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in C57BL/6 mice. Neurosci Lett 314 49-52.
107. R. Morigaki, W. Sako, S. Okita, et al. (2011) Cyclin-dependent kinase 5 with phosphorylation of tyrosine 15 residue is enriched in striatal matrix compartment in adult mice. Neuroscience 189 25-31.
108. K. Ishiwata, Y. Koyanagi, K. Abe, et al. (2001) Evaluation of neurotoxicity of TIQ and MPTP and of parkinsonism-preventing effect of 1-MeTIQ by in vivo measurement of pre-synaptic dopamine transporters and post-synaptic dopamine D(2) receptors in the mouse striatum. J Neurochem 79 868-876.
109. M. Honer, B. Hengerer, M. Blagoev, et al. (2006) Comparison of [18F]FDOPA, [18F]FMT and [18F]FECNT for imaging dopaminergic neurotransmission in mice. Nucl Med Biol 33 607-614.
110. K.T. Chao, H.H. Tsao, Y.H. Weng, et al. (2012) Quantitative analysis of binding sites for 9-fluoropropyl-(+)-dihydrotetrabenazine ([(18F)]AV-133) in a MPTP-lesioned PD mouse model. Synapse 66 823-831.
111. J.S. Toomey, S. Bhatia, L.T. Moon, et al. (2012) PET Imaging a MPTP-induced mouse model of Parkinson's disease using the fluoropropyl-dihydrotetrabenazine analog [(18)F]-DTBZ (AV-133). PLoS One 7 e39041.
112. H. Mashiko, A.C. Yoshida, S.S. Kikuchi, et al. (2012) Comparative anatomy of marmoset and mouse cortex from genomic expression. J Neurosci 32 5039-5053.
113. S. Rose, M. Nomoto, E.A. Jackson, et al. (1993) Age-related effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment of common marmosets. Eur J Pharmacol 230 177-185.
114. L. Minuzzi, A.K. Olsen, D. Bender, et al. (2006) Quantitative autoradiography of ligands for dopamine receptors and transporters in brain of Göttingen minipig: comparison with results in vivo. Synapse 59 211-219.